BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17693194)

  • 1. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
    Weisser M; Haferlach C; Haferlach T; Schnittger S
    Cancer Genet Cytogenet; 2007 Aug; 177(1):64-9. PubMed ID: 17693194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
    Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
    Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
    Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia.
    Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L
    Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W; Schoch C; Haferlach T; Schnittger S
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
    Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
    Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
    Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
    Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
    J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined application of multiplex reverse transcription-polymerase chain reaction and karyotype analysis to detection of clonal chromosomal aberrations in acute myeloid leukemia].
    Huang L; Li CR; Zhang H; Sun LS; Liu WL; Zhou JF
    Ai Zheng; 2007 Sep; 26(9):1029-33. PubMed ID: 17927867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.
    Lahortiga I; Vázquez I; Agirre X; Larrayoz MJ; Vizmanos JL; Gozzetti A; Calasanz MJ; Odero MD
    Genes Chromosomes Cancer; 2004 Jul; 40(3):179-89. PubMed ID: 15138998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
    Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
    Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events.
    Debernardi S; Lillington DM; Chaplin T; Tomlinson S; Amess J; Rohatiner A; Lister TA; Young BD
    Genes Chromosomes Cancer; 2003 Jun; 37(2):149-58. PubMed ID: 12696063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.